Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects

Table 3

Mean body weight changes throughout the study. Full analysis set.

Body weight (kg), mean ± s.d.	IQP-AE-103 LD ()	IQP-AE-103 HD ()	Placebo ()
Baseline	84.42 ± 14.89	84.04 ± 10.56	86.77 ± 15.27
Week 2	83.83 ± 15.12	83.18 ± 10.35	86.43 ± 15.30
Week 4	83.18 ± 15.48	82.13 ± 10.35	85.99 ± 15.29
Week 8	82.44 ± 15.61	81.04 ± 10.35	85.89 ± 15.34
Week 12	81.41 ± 15.82	79.01 ± 9.89	85.79 ± 15.46
Baseline-week 2	0.59 ± 0.95	0.87 ± 1.16	0.34 ± 0.95
Baseline-week 4	1.24 ± 1.37	1.91 ± 1.39^a	0.78 ± 1.44
Baseline-week 8	1.98 ± 1.81^a	3.01 ± 1.69^a,b	0.88 ± 1.87
Baseline-week 12	3.01 ± 2.19^a	5.03 ± 2.50^a,b	0.98 ± 2.06

LD = low dose; HD = high dose; ^asignificant difference vs. placebo; ^bsignificant difference vs. IQP-AE-103 LD.